Table 2

Treatment outcomes stratified by treatment group and day of follow-up
Outcome Measure by Day
 No./Total (%) of Patients [95% CI]




CQ

SP

AQ

ASAQ

Day 14
Clinical failure
 ETF
 14/309
 (4.5)
 [2.6–7.3]
 4/368
 (1.1)
 [0.3–2.6]
 2/372
 (0.5)
 [0.1–1.7]
 0/335
 (0)

LCF
 29/309
 (9.4)
 [6.5–13.0]
 2/368
 (0.5)
 [0.1–1.7]
 0/372
 (0)
0/335
 (0)
Parasitological failure
 LPF
 56/309
 (18.1)
 [14.1–22.7]
 3/368
 (0.8)
 [0.2–2.2]
 0/372
 (0)
0/335
 (0)
Overall Treatment failure
99/309
 (32.0)
 [27.0–37.4]
 9/368
 (2.4)
 [1.2–4.4]
 2/372
 (0.5)
 [0.1–1.7]
 0/335
 (0)
Day 28 Unadjusted by genotyping
Clinical failure
 ETF
 14/300
 (4.7)
 [2.7–7.5]
 4/361
 (1.1)
 [0.4–2.7]
 2/356
 (0.6)
 [0.1–1.8]
 0/330
 (0)

LCF
 45/300
 (15.0)
 [11.3–19.4]
 4/361
 (1.1)
 [0.4–2.7]
 3/356
 (0.8)
 [0.2–2.3]
 4/330
 (1.2)
 [0.4–2.9]
Parasitological failure
 LPF
 104/300
 (34.7)
 [29.4–40.2]
 8/361
 (2.2)
 [1.0–4.2]
 6/356
 (1.7)
 [0.7–3.5]
 8/330
 (2.4)
 [1.1–4.6]
Overall Treatment failure
163/300
 (54.4)
 [48.7–59.9]
 16/361
 (4.4)
 [2.6–6.9]
 11/356
 (3.1)
 [1.6–5.3]
 12/330
 (3.6)
 [2.0–6.1]
Day 28 Adjusted by genotyping
Clinical failure
 ETF
 14/300
 (4.7)
 [2.7–7.5]
 4/361
 (1.1)
 [0.4–2.7]
 2/356
 (0.6)
 [0.1–1.8]
 0/330
 0
 [0.4–2.7]

LCF
 34/300
 (11.3)
 [8.1–15.3]
 3/361
 (0.8)
 [0.2–2.2]
 1/356
 (0.3)
 [0–1.4]
 2/330
 (0.6)
 [0.1–2.0]
Parasitological failure
 LPF
 84/300
 (28.0)
 [23.1–33.3]
 5/361
 (1.4)
 [0.5–3.0]
 3/356
 (0.8)
 [0.2–2.3]
 4/330
 (1.2)
 [0.4–2.9]
Overall Treatment failure
132/300
 (44.0)
 [38.5–49.7]
 12/361
 (3.3)
 [1.8–5.6]
 6/356
 (1.7)
 [0.7–3.5]
 6/330
 (1.8)
 [0.7–3.7]

CI: Confidence Interval; ETF: Early Treatment Failure; LCF: Late Clinical Failure; LPF: Late Parasitological Failure; CQ: Chloroquine; AQ: Amodiaquine; ASAQ: Artesunate + Amodiaquine; SP: Sulphadoxine-Pyrimethamine

Ménard et al. Malaria Journal 2008 7:55   doi:10.1186/1475-2875-7-55